This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, L. W. Search for Related Content PubMed PubMed Citation Articles by Miller, L. W. Related Collections Congestive Other Treatment

(Circulation. 2008;118:1223-1224.)
© 2008 American Heart Association, Inc.

Editorial

Continuous Aortic Flow Augmentation

Not Enough MOMENTUM

Leslie W. Miller, MD

From Washington Hospital Center and Georgetown University Hospital, Washington, DC.

Correspondence to Leslie Miller, MD, Washington Hospital Center, 110 Irving St NW, Room 1E-11, Washington, DC 20010. E-mail leslie.w.miller@medstar.net

Key Words: Editorials • heart-assist device • heart failure • hemodynamics • vasodilation

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The study by Greenberg et al¹ published in this issue of Circulation details the results of the randomized clinical trial known as the Multicenter trial of the Orqis Medical Cancion system for the ENhanced Treatment of heart failure Unresponsive to Medical therapy (MOMENTUM). The Orqis device is a new entry into the field of temporary mechanical circulatory support for severe heart failure. The authors point to the growing number of patients with this condition and the very high in-hospital and short-term mortalities that are typically associated with conventional medical or surgical therapy. Thus, new simple methods of providing temporary circulatory support to allow identification of individuals with reversible dysfunction to improve, while adequately supporting the circulation to prevent multiorgan failure and the high likelihood of death in those without improvement in cardiac function, would be a significant advance in management of this population.

Article p 1241

Conducting clinical trials on patients who are this ill with very advanced heart failure is, understandably, very difficult, owing to the presence of multiple comorbidities with adverse events that are, potentially, not a direct result of the therapy being evaluated. The cohort of 168 patients enrolled in the MOMENTUM trial¹ were typical of this population, with low blood pressure and cardiac output as well as impaired renal function despite intravenous inotrope and/or vasodilator therapy. The trial randomized patients to optimal medical therapy with or without addition of the continuous aortic flow augmentation device. The primary composite end point was a reduction in pulmonary capillary . . . [Full Text of this Article]

This article has been cited by other articles:

				B. Greenberg Letter by Greenberg Regarding Article, "Continuous Aortic Flow Augmentation: Not Enough MOMENTUM" Circulation, April 14, 2009; 119(14): e389 - e389. [Full Text] [PDF]

				L. W. Miller Response to Letter Regarding Article, "Continuous Aortic Flow Augmentation: Not Enough MOMENTUM" Circulation, April 14, 2009; 119(14): e390 - e390. [Full Text] [PDF]